Interleukin-6 inhibition of peroxisome proliferator-activated receptor alpha expression is mediated by JAK2- and PI3K-induced STAT1/3 in HepG2 hepatocyte cells

Molecular and Cellular Biochemistry

Volumn 388, Issue 1-2, 2014, Pages 25-37

  Chew, Guat Siew ^a,b   Myers, Stephen ^b   Shu Chien, Alexander Chong ^a   Muhammad, Tengku Sifzizul Tengku ^c  

^a SCHOOL OF PHYSICS   (Malaysia)

^b UNIVERSITY OF BALLARAT   (Australia)

^c UNIVERSITI MALAYSIA TERENGGANU   (Malaysia)

Author keywords

Acute phase response; Cell signaling pathways; Human HepG2 hepatocyte cells; Interleukin 6; Peroxisome proliferator alpha

Indexed keywords

ACUTE-PHASE REACTION; ANDROSTADIENES; BINDING SITES; CELL LINE, TUMOR; HEP G2 CELLS; HEPATOCYTES; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PPAR ALPHA; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, MESSENGER; SIROLIMUS; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC; TYRPHOSTINS;

EID: 84893870189     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1896-z     Document Type: Article

References (84)

1. Bode JG, Albrecht U, Häussinger D, Heinrich PC, Schaper F (2012) Hepatic acute phase proteins - regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. Eur J Cell Biol 91:496-505
2. Gruys E, Toussaint MJM, Niewold TA, Koopmans SJ (2005) Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci 6B:1045-1056 (Pubitemid 43083934)
3. Lowenstein C, Matsushita K (2004) The acute phase response and the atherosclerosis. Drug Discov Today Dis Mech 1:17-22 (Pubitemid 41128986)
4. Gomez CR, Goral J, Ramirez L, Kopf M, Kovacs EJ (2006) Aberrant acute-phase response in aged interleukin-6 knockout mice. Shock 25:581-585 (Pubitemid 44297018)
5. Febbraio MA, Rose-John S, Pedersen BK (2010) Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin Pharmacol Ther 87:396-398
6. Matthews VB, Allen TL, Risis S, Chan MHS, Henstridge DC, Watson N, Zaffino LA, Babb JR, Boon J, Meikle PJ, Jowett JB, Watt MJ, Jansson JO, Bruce CR, Febbraio MA (2010) Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 53:2431-2441
7. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454 (Pubitemid 29084777)
8. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 445:1169-1196 (Pubitemid 38802622)
9. Kishimoto T (2010) IL-6: from its discovery to clinical applications. Int Immunol 22:347-352
10. Dhainaut JF, Marin N, Mignon A, Vinsonneau C (2001) Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 29:S42-S47
11. Hoffmeister A, Rothenbacher D, Bazner U, Frohlich M, Brenner H, Hombach V, Koenig W (2001) Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 87:262-266 (Pubitemid 32144863)
12. Neurath M, Finotto S (2011) IL-6 signalling in autoimmunity chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22:83-89
13. Yudkin JS, Kumari M, Humpries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin the link? Atherosclerosis 148:209-214 (Pubitemid 30064452)
14. Hoang T, Haman A, Goncalves O, Wong GG, Clark SC (1988) Interleukin-6 enhances growth factor-dependent proliferation of the blast cells of acute myeloblastic leukemia. Blood 72:823-826
15. Wang FW, Hao HB, Zhao SD, Zhang YM, Liu Q, Liu HJ, Liu SM, Yuan QH, Bing LJ, Ling EA, Hao AJ (2011) Roles of activated astrocyte in neural stem cell proliferation and differentiation. Stem Cell Res 7:41-53
16. Ganapathi MK, Rzewnicki D, Samols D, Jiang SL, Kushner I (1991) Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J Immunol 147:1261-1265
17. Daveau M, Davrinche C, Julen H, Hiron M, Arnaud P, Lebreton JP (1988) The synthesis of human α-2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS Lett 241:191-194 (Pubitemid 19005004)
18. Koj A, Gordon HH, Gauldie J (1988) An alternative regulatory pathway of the acute phase response: the role of fibroblast-derived interferon-beta 2. Experientia 44:9-10 (Pubitemid 18058080)
19. Mackiewicz A, Kushner I (1989) Interferon β2/B-cell stimulating factor 2/interleukin 6 affects glycosylation of acute phase proteins in human hepatoma cell lines. Scand J Immunol 29:265-271 (Pubitemid 19085376)
20. Chew CH, Chew GS, Najimudin N, Tengku-Sifzizul TM (2007) Interleukin-6 inhibits human peroxisome proliferator activated receptor alpha gene expression via CCAAT/enhancer-binding protein in hepatocytes. Int J Biochem Cell Biol 39:1975-1986 (Pubitemid 47334903)
21. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ (2001) Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol 21:1393-1403 (Pubitemid 32114986)
22. Wang Z, Burke PA (2007) Effects of hepatocyte nuclear factor-4α on the regulation of the hepatic acute phase response. J Mol Biol 371:323-335 (Pubitemid 47049809)
23. Lee CH, Olson P, Evans RM (2003) Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144:2201-2207 (Pubitemid 36629867)
24. Myers SA, Wang S-CM, Muscat GEO (2006) The chicken ovalbumin upstream promoter-transcription factors modulate genes and pathways involved in skeletal muscle cell metabolism. JBC 281:24149-24160 (Pubitemid 44274189)
25. Panzenboeck U, Kratzer I, Sovic A, Wintersperger A, Bernhart E, Hammer A, Malle E, Sattler W (2006) Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells. Int J Biochem Cell Biol 38:1314-1329
26. Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, Kooistra T (2004) Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-α activator fenofibrate. J Biol Chem 279:16154-16160 (Pubitemid 38509307)
27. Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B (2002) The role of PPARs in atherosclerosis. Trends Mol Med 8:422-430 (Pubitemid 34975988)
28. van Raalte DH, Li M, Pritchard PH, Wasan KM (2005) Peroxisome proliferator-activated receptor alpha (PPARα): a pharmacological target with a promising future. Pharm Res 21:1531-1538
29. Jonkers IJ, Mohrschladt MF, Westendorp RG, Van der Laarse A, Smelt AH (2002) Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 12:275-280 (Pubitemid 34219440)
30. Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR (2000) The acute phase response is associated with retinoid X receptor repression in rodent liver. J Biol Chem 275:16390-16391 (Pubitemid 30366957)
31. Fang C, Yoon S, Tindberg N, Jarvelainen HA, Lindros KO, Ingelman-Sundberg M (2004) Hepatic expression of multiple acute phase proteins and down regulation of nuclear receptors after acute endotoxin exposure. Biochem Pharmacol 67:1389-1397 (Pubitemid 38315104)
32. Feingold K, Kim MS, Shigenaga J, Moser A, Grunfeld C (2004) Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute phase response. Am J Physiol Endocrinol Metab 286:E201-E207
33. Lee TI, Kao YH, Chen YC, Che YJ (2008) Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptor. Eur J Clin Investig 39:23-30
34. Chew CH, Samian MR, Najimudin N, Tengku-Muhammad TS (2003) Molecular characterization of six alternatively spliced variants and novel promoter in human peroxisome proliferator activated receptor α. Biochem Biophys Res Commun 305:235-243 (Pubitemid 36555458)
35. Elliot J (2008) Soc3 in liver regeneration and hepatocarcinoma. Mol Interv 8:19-21 (Pubitemid 351398448)
36. Qian Y, Deng J, Xie H, Geng L, Zhou L, Wang Y, Yin S, Feng X, Zheng S (2009) Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling. J Cancer Res Clin Oncol 135:379-386
37. Kwak SY, Kim UK, Cho HJ, Lee HK, Kim HJ, Kim NK et al (2008) Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) gene polymorphisms as risk factors for hepatocellular carcinoma in a Korean population. Anticancer Res 28:2807-2811
38. Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS, Huang CYF (2005) IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 289:446-453 (Pubitemid 41192720)
39. Samardzija M, Wenzel A, Aufenberg S, Thiersch M, Remé C, Grimm C (2006) Differential role of JAK-STAT signaling in retinal degenerations. FASEB J 20:2411-2413 (Pubitemid 44953843)
40. Tomita Y, Morooka T, Hoshida Y, Zhang B, Qiu Y, Hamada K et al (2006) Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res 12:3070-3077 (Pubitemid 43837353)
41. Morgensztern D, McLeod HL (2005) PI3K/AKT/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16:797-803 (Pubitemid 41215743)
42. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X et al (2000) Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/AKT pathway in human ovarian cancer. Oncogene 19:2324-2330 (Pubitemid 30307208)
43. Quandt K, Frech K, Karas H, Wingender E, Werner T (1995) MatInd and MatInspector: new fast and versatile tolls for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 23:4878-4884 (Pubitemid 3008389)
44. Yu H, Li X, Marchetto GS, Dy R, Hunter D, Calvo B et al (1996) Activation of a novel calcium-dependent protein-tyrosine kinase. Correlation with c-Jun N-terminal kinase but not mitogen-activated protein kinase activation. J Biol Chem 271:29993-29998 (Pubitemid 26389637)
45. Bauzá G, Miller G, Kaseje N, Wigner NA, Wang Z, Gerstenfeld LC, Burke PA (2011) The effects of injury magnitude on the kinetics of the acute phase response. J Trauma 70:948-953
46. Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B (2006) Modulation of hepatic inflammatory risk markers of cardiovascular disease by PPARα activators clinical and experimental evidence. Arterioscler Thromb Vasc Biol 26:977-986 (Pubitemid 43732101)
47. Schuringa JJ, Jonk LJ, Dokter WH, Vellenga E, Kruijer W (2000) Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components. Biochem J 347:89-96 (Pubitemid 30199045)
48. Tron K, Samoylenko A, Musikowski G, Kobe F, Immenschuh S, Schaper F et al (2006) Regulation of rat heme oxygenase-1 expression by interleukin-6 via the JAK/STAT pathway in hepatocytes. J Hepatol 45:72-80 (Pubitemid 43850615)
49. Yeoh CT, Ernst M, Rose-John S, Akhurst B, Payne C, Long S et al (2007) Opposing roles of gp130-mediated STAT-3 and ERK-1/2 signaling in liver progenitor cell migration and proliferation. J Hepatol 45:486-494 (Pubitemid 46374605)
50. Brand S, Dambacher J, Beigel F, Zitzmann K, Heeg MHJ, Weiss TS et al (2007) IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am J Physiol Gastrointest Liver Physiol 292:1019-1028 (Pubitemid 46557789)
51. Markiewski M, DeAngelis R, Strey C, Foukas P, Gerard C, Gerard N, Wetse R, Lambris J (2009) The regulation of liver cell survival by complement. J Immunol 182:5412-5418
52. Darnell JE Jr, Kerr IM, Stark GR (1994) JAK/STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421 (Pubitemid 24217131)
53. Schaper F, Gendo C, Eck M, Schmitz J, Grimm C, Anhuf D et al (1998) Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase JAK1 and limits acute-phase protein expression. Biochem J 335:557-565 (Pubitemid 28515408)
54. Bashkar K, Miller M, Chludzinski A, Herrup K, Zagorski M, Lamb BT (2009) The PI3K-AKT-mTOR pathway regulates Aβ oligomer induced neuronal cell cycle events. Mol Neurodegener 4:14-32
55. Cartot A, Armand JP, Soria JC (2006) PI3K-AKT-mTOR pathway inhibitors. Bull Cancer 93:19-26
56. Whittaker S, Marais R, Zhu AX (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 26:1829-1839
57. Hong F, Nguyen VA, Shen X, Kunos G, Gao B (2000) Rapid activation of protein kinase B/AKT has a key role in antiapoptotic signaling during liver regeneration. Biochem Biophys Res Commun 279:974-979 (Pubitemid 32042887)
58. Taub R (2004) Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 5:836-847 (Pubitemid 39336277)
59. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501 (Pubitemid 37328931)
60. Chiang PH, Wang L, Bonham CA, Liang X, Fung JJ, Lu L et al (2004) Mechanistic insights into impaired dendritic cell function by rapamycin: inhibition of JAK2/STAT4 signaling pathway. J Immunol 172:1355-1363 (Pubitemid 38116776)
61. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM (2003) Rapamycin inhibits the interleukin 10 signal transduction pathways and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 63:4472-4480 (Pubitemid 36951019)
62. Kim JH, Kim JE, Liu HY, Cao W, Chen J (2007) Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J Biol Chem 283:708-715
63. Vogt PK, Hart JR (2011) PI3K and STAT3: a new alliance. Cancer Discov 1:481-486
64. Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H et al (2008) STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Investig 118:1727-1738 (Pubitemid 351632376)
65. Hong F, Kim WH, Tian Z, Jaruga B, Ishac E, Shen X, Gao B (2002) Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-x(L) proteins. Oncogene 21:32-43 (Pubitemid 34076376)
66. de Wolf CJF, Cupers RMJ, Bertina RM, Vos HL (2006) Interleukin-6 induction of protein S is regulated through signal transducer and activator transcription 3. Arterioscler Thromb Vasc Biol 26:2168-2174 (Pubitemid 44253804)
67. Ruminy P, Gangneux C, Claeyssens S, Scotte M, Daveau M, Salier JP (2001) Gene transcription in hepatocytes during the acute phase of a systemic inflammation: from transcription factors to target genes. Inflamm Res 50:383-390 (Pubitemid 32777664)
68. Heinrich PC, Behmann I, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1-20 (Pubitemid 37046923)
69. Levy DE, Darnell JE Jr (2002) STATs: transcriptional control and biological impact. Mol Cell Biol 3:651-662 (Pubitemid 34987786)
70. Lim CP, Cao X (2006) Structure, function, and regulation of STAT proteins. Mol Biosyst 2:536-550 (Pubitemid 44583902)
71. Kaelin CB, Gong L, Xu AW, Yao F, Hockman K, Morton GJ, Schwartz MW, Barsh G, MacKenzie RG (2006) Signal transducer and activator of transcription (STAT) binding sites but not STAT3 are required for fasting-induced transcription of agouti-related protein messenger ribonucleic acid. Mol Endocrinol 20:2591-2602 (Pubitemid 44496426)
72. Roglans N, Vila L, Farre M, Alegret M, Sanchez RM, Vazquez-Carrera M, Laguna JC (2007) Impairment of hepatic STAT3 activation and reduction of PPARα activity in fructose-fed rats. Hepatology 45:778-788 (Pubitemid 46450629)
73. Zhou YC, Waxman DJ (1999) Cross-talk between Janus kinase-signal transducer and activator of transcription (JAK-STAT) and the peroxisome proliferator activated receptor α (PPAR α) signaling pathways. Growth hormone inhibition of PPARα transcriptional activity mediated by STAT5b. J Biol Chem 274:2672-2681 (Pubitemid 29075346)
74. Hogan JC, Stephens JM (2001) The identification and characterization of a STAT1 binding site in the PPARγ2 promoter. Biochem Biophys Res Commun 287:484-492 (Pubitemid 32917624)
75. Mráček T, Cannon B, Houštěk J (2004) IL-1 and LPS but not IL-6 inhibit differentiation and downregulate PPAR gamma in brown adipocytes. Cytokine 26:9-15 (Pubitemid 38317409)
76. Tanaka T, Itoh H, Doi K, Fukunaga Y, Hosoda K, Shintani M et al (1999) Down regulation of peroxisome proliferator-activated receptor g expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia 42:702-710 (Pubitemid 29265588)
77. Waite KJ, Floyd ZE, Arbour-Reily P, Stephens JM (2001) Interferon-γ-induced regulation of peroxisome proliferator-activated receptor gamma and STATs in adipocytes. J Biol Chem 276:7062-7068
78. Haspel RL, Darnell JE Jr (1999) A nuclear protein tyrosine phosphatase is required for the inactivation of STAT1. Proc Natl Acad Sci USA 96:10188-10193 (Pubitemid 29422534)
79. Luo G, Yu-Lee LY (1997) Transcriptional inhibition by STAT5: differential activities at growth-related versus differentiation-specific promoters. J Biol Chem 272:26841-26846 (Pubitemid 27452631)
80. 2M in the rat ovary. Biol Reprod 55:1029-1038 (Pubitemid 26346537)
81. Zvonic S, Hogan JC, Arbour-Reily P, Mynatt RL, Stephens JM (2004) Effects of cardiotrophin on adipocytes. J Biol Chem 279:47572-47579 (Pubitemid 39540902)
82. Krasilnikov M, Ivanov VN, Dong J, Ronai Z (2003) ERK and PI3K negatively regulate STAT transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 22:4092-4101 (Pubitemid 36819649)
83. Lee HK, Seo IA, Shin YK, Park JW, Suh DJ, Park HT (1997) Capsaicin inhibits the IL-6/STAT3 pathway by depleting intracellular gp130 pools through endoplasmic reticulum stress. Biochem Biophys Res Commun 382:445-450
84. Decker T, Kovarik P (1999) Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins. Cell Mol Life Sci 55:1535-1546 (Pubitemid 29445819)